EUVIMEDEUVIMED entdecken
Open Access · CC0

Trends in hepatocellular carcinoma and viral hepatitis treatment in older Americans

Joy Jiang, Meredith S Shiels, Donna Rivera, Marc G Ghany, Eric A Engels, Thomas R O'Brien

PLOS ONE · 2024

DOI: 10.1371/journal.pone.0307746 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS ONE, 2024. Verfasst von Joy Jiang und 5 weiteren Autor:innen. Beteiligte Einrichtung: Infections and Immunoepidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Maryland, United States …. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, Antiviral Agents, SEER Program. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Incidence of hepatocellular carcinoma (HCC) had been increasing steadily among older Americans but plateaued in 2015–2017. Chronic infection with hepatitis B virus (HBV) or hepatitis C virus (HCV) are important causes of HCC. The impact of improved treatments for these infections on recent trends in HCC incidence is unclear.

Aims

To examine the relationship between use of antiviral therapy for chronic viral hepatis and HCC incidence in older Americans.

Methods

We used 2007–2017 data from the Surveillance, Epidemiology, and End Results—Medicare database to estimate age-standardized incidence rates and average annual percent changes (AAPCs) for viral hepatitis-attributable HCC among individuals ≥66 years. We analyzed data from Medicare Part D to determine the frequency of HBV and HCV treatment utilization in this population.

Results

Overall HCC incidence increased 10.5%, from 22.2/100,000 in 2007 to 24.5/100,000 in 2017 (AAPC, 1.3%). During that time, HBV-attributable HCC rates decreased from 2.5 to 2.0/100,000 (AAPC, -1.6%), while HCV-attributable HCC rose from 6.6 to 8.0/100,000 (AAPC, 2.0%). HBV treatment among patients with HBV infection increased by 66% (2007, 7.4%; 2015, 12.3%). Treatment for HCV was stable at

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, HepatocellularLiver NeoplasmsAntiviral AgentsSEER ProgramHumansAgedUnited StatesMaleFemaleIncidenceAged, 80 and overHepatitis C, ChronicHepatitis B, Chronic

Substanzen

Antiviral Agents

Autor:innen und Institutionen

  • Infections and Immunoepidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Maryland, United States of America.
  • Division of Cancer Control and Population Sciences, National Cancer Institute, Rockville, Maryland, United States of America.
  • Clinical Research Section, Liver Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, Maryland, United States of America.

Zitieren

APA

Jiang, J., Shiels, M. S., Rivera, D., Ghany, M. G., Engels, E. A., & O'Brien, T. R. (2024). Trends in hepatocellular carcinoma and viral hepatitis treatment in older Americans. PLOS ONE. https://doi.org/10.1371/journal.pone.0307746

Vancouver

Jiang J, Shiels MS, Rivera D, Ghany MG, Engels EA, O'Brien TR. Trends in hepatocellular carcinoma and viral hepatitis treatment in older Americans. PLOS ONE. 2024. doi:10.1371/journal.pone.0307746

BibTeX
@article{Jiang2024,
  author = {Jiang, Joy and Shiels, Meredith S and Rivera, Donna and Ghany, Marc G and Engels, Eric A and O'Brien, Thomas R},
  title = {Trends in hepatocellular carcinoma and viral hepatitis treatment in older Americans},
  journal = {PLOS ONE},
  year = {2024},
  doi = {10.1371/journal.pone.0307746}
}
Kostenlos starten →